株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

膵臓癌治療法の世界市場:2019年〜2023年

Global Pancreatic Cancer Therapeutics Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 773850
出版日 ページ情報 英文 115 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.55円で換算しております。
Back to Top
膵臓癌治療法の世界市場:2019年〜2023年 Global Pancreatic Cancer Therapeutics Market 2019-2023
出版日: 2018年12月27日 ページ情報: 英文 115 Pages
概要

改善された診断法の有用性が市場成長を推進:膵臓癌の予後における欠点を克服するために、相補的DNA (cDNA) フィンガープリント法、PCR、およびDNAマイクロアレイの原理に基づく先進の診断補助剤、および分子プロファイリングが開発されています。 Technavioのアナリストは、世界の膵臓癌治療法市場が2023年までに8%以上のCAGRで成長すると予測しています。

当レポートでは、世界の膵臓癌治療法市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 レポートの範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場エコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 パイプライン分析

第5章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年〜2023年)

第6章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第7章 市場セグメンテーション:製品別

  • 市場セグメンテーション:製品別
  • 製品別比較:市場規模および予測(2018年〜2023年)
  • ターゲット療法
  • 化学療法
  • 市場機会:製品別

第8章 顧客情勢

第9章 市場セグメンテーション:タイプ別

  • 膵外分泌癌
  • 膵内分泌癌

第10章 地域情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年〜2023年)
  • 南北アメリカ
  • 欧州・中東・アフリカ地域
  • アジア太平洋地域
  • 主要国
  • 市場機会

第11章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第12章 市場動向

第13章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第14章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Shire

第15章 付録

  • 調査方法
  • 略語のリスト
図表
  • Exhibit 01: Years in consideration
  • Exhibit 02: Global oncology therapeutics market
  • Exhibit 03: Segments of global oncology therapeutics market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Therapies in late stage development for pancreatic cancer
  • Exhibit 07: Market definition - Inclusions and exclusions checklist
  • Exhibit 08: Market size 2018
  • Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 11: Five forces analysis 2018
  • Exhibit 12: Five forces analysis 2023
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2018
  • Exhibit 19: Product - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by product
  • Exhibit 21: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Targeted therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Chemotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by product
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Key leading countries
  • Exhibit 36: Market opportunity
  • Exhibit 37: Decision framework
  • Exhibit 38: New drug approvals for pancreatic cancer
  • Exhibit 39: Patent expiration dates for therapies for pancreatic cancer
  • Exhibit 40: Impact of drivers and challenges
  • Exhibit 41: Immunotherapy products under research
  • Exhibit 42: Combination therapies for pancreatic cancer
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: Eli Lilly - Vendor overview
  • Exhibit 49: Eli Lilly - Business segments
  • Exhibit 50: Eli Lilly - Organizational developments
  • Exhibit 51: Eli Lilly - Geographic focus
  • Exhibit 52: Eli Lilly - Segment focus
  • Exhibit 53: Eli Lilly - Key offerings
  • Exhibit 54: F. Hoffmann-La Roche - Vendor overview
  • Exhibit 55: F. Hoffmann-La Roche - Business segments
  • Exhibit 56: F. Hoffmann-La Roche - Organizational developments
  • Exhibit 57: F. Hoffmann-La Roche - Geographic focus
  • Exhibit 58: F. Hoffmann-La Roche - Segment focus
  • Exhibit 59: F. Hoffmann-La Roche - Key offerings
  • Exhibit 60: Novartis - Vendor overview
  • Exhibit 61: Novartis - Business segments
  • Exhibit 62: Novartis - Organizational developments
  • Exhibit 63: Novartis - Geographic focus
  • Exhibit 64: Novartis - Segment focus
  • Exhibit 65: Novartis - Key offerings
  • Exhibit 66: Pfizer - Vendor overview
  • Exhibit 67: Pfizer - Business segments
  • Exhibit 68: Pfizer - Organizational developments
  • Exhibit 69: Pfizer - Geographic focus
  • Exhibit 70: Pfizer - Segment focus
  • Exhibit 71: Pfizer - Key offerings
  • Exhibit 72: Shire - Vendor overview
  • Exhibit 73: Shire - Business segments
  • Exhibit 74: Shire - Organizational developments
  • Exhibit 75: Shire - Geographic focus
  • Exhibit 76: Shire - Key offerings
  • Exhibit 77: Validation techniques employed for market sizing
  • Exhibit 78: List of abbreviations
目次
Product Code: IRTNTR30555

About this market

Availability of improved diagnostic modalities to drive growth in the market. To combat the shortcomings in the prognosis of pancreatic cancer, advanced diagnostic aids based on the principles of complementary DNA (cDNA) fingerprinting, PCR, and DNA microarray, and molecular profiling are being developed. Technavio's analysts have predicted that the pancreatic cancer therapeutics market will register a CAGR of more than 8% by 2023.

Market Overview

Robust pipeline and new drug approvals

The pipeline for the treatment of pancreatic cancer includes novel therapeutic approaches, including vaccines, gene therapy, stem cell therapy, and targeted therapy products.

High cost of treatments

Pancreatic cancer requires long term treatment, which increases the treatment cost and the economic burden on patients.

For the detailed list of factors that will drive and challenge the growth of the pancreatic cancer therapeutics market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Pfizer and Shire the competitive environment is quite intense. Factors such as the robust pipeline and new drug approvals and the availability of improved diagnostic modalities, will provide considerable growth opportunities to pancreatic cancer therapeutics manufactures. Eli Lilly, F. Hoffmann-La Roche, Novartis, Pfizer, and Shire are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$
4

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Targeted therapy - Market size and forecast 2018-2023
  • Chemotherapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE

  • Exocrine pancreatic cancer
  • Endocrine pancreatic cancer

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Novartis
  • Pfizer
  • Shire

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations
Back to Top